Integra LifeSciences Holdings Corporation
) announced the first human implantation of its U.S. Food and
Drug Administration (FDA) approved Integra Laminoplasty System in
the U.S. The system is designed for treating patients with
ossification of the posterior longitudinal ligament, cervical
myelopathy and degenerative spinal canal stenos.
The Laminoplasty System is composed of a wide range of robust,
arched plate designs, self-drilling bone screws and multiple
insertion options. The system proved itself to be user friendly
during the implantation procedure. The arched radius of the plate
allows for spinal canal expansion. Moreover, the foot on the
plate provides efficient initial stability.
The Laminoplasty System is a part of Integra's Spine segment
which accounted for 21.5% of the company's total revenue in 2013.
In a bid to strengthen this segments offering, Integra introduced
the FDA approved Integra Hollywood NanoMetalene Interbody Device
(IBD). The IBD is used primarily in transforaminal lumbar
interbody fusion (TLIF).
Integra has strengthened its claim for the leadership position in
the global laminoplasty market which is estimated to reach
approximately $70 million by 2015. However, we would like to
remain on the sidelines at present unless some visibility is
gained regarding the acceptability and performance of Integra's
Laminoplasty system in the market.
Integra currently bears a Zacks Rank #3 (Hold). Some
better-ranked stocks worth considering in the overall medical
Alexion Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc.
). All these stocks carry a Zacks Rank #1 (Strong Buy).
ALKERMES INC (ALKS): Free Stock Analysis
ANI PHARMACEUT (ANIP): Free Stock Analysis
INTEGRA LIFESCI (IART): Free Stock Analysis
To read this article on Zacks.com click here.